Management

Christopher C. Gallen, CEO

Dr. Gallen trained initially in Philosophy (University of Florida) then trained as a Medical Scientist (M.D., Ph.D., Emory), psychiatrist (Stanford) and neurologist (UCSD) then led an innovative career as an academician (The Scripps Research Institute) where his laboratory with great collaborators pioneered the use of Magnetic Source Imaging developing the first clinical indications for the technology, made important scientific discoveries (including the first demonstration of human cerebral plasticity and of the 40 Hz current in man) and acted as a scientific spokesman supporting the NADAQ IPO of BTi. Dr. Gallen then joined Quintiles, rising to Sr. Medical Director, where he drove pivotal trials of several therapeutics that became registered for CNS and other disorders.

Dr. Gallen then became President of the nascent Premier Research Worldwide (PRWW) and with great staff innovated the first use of Remote Data Capture into the Clinical Research Organization (CRO) field, (an approach now circa >95% of CRO data handling globally), introduced Computer Assisted Research and Development (CARD) into clinical research, played a key role in developing the therapeutic that became XYREMTM led PRWW to become a public company through a NASDAQ IPO then grew the company to international status. Dr. Gallen then joined Pharmacia as VP Medical Research where he led CNS development and/or registration of several therapeutics, managed clinical operations for all therapeutic areas in the Americas, played a leadership role in the successful re-engineering of Pharmacia clinical and was promoted to Site Head R&D for the Kalamazoo site.

Dr. Gallen next became VP Clinical Operations at Wyeth where, enabled by great staff and collaborators, he led a transformative reorganization that produced top tier industry performance, created the Alliance for Clinical Excellence (ACE) with Accenture (the first large scale industry movement into use of India for data management), and developed what emerged as the Functional Services Model for managing out-sourcing, now one of the main industry models globally. Dr. Gallen next became CEO of Vancouver-based Neuromed, negotiated a large collaboration with Merck, in-licensed OROS-hydromorphone from Alza, took Neuromed public becoming CEO of Combinatorx and later, as head of R&D, registered EXALGO™. Immediately prior to joining WEX Pharmaceuticals Inc., Dr. Gallen was CEO of SK Biopharmaceuticals, the first Western CEO of a major Korean pharmaceutical company, led its fine staff in significant advancement - moving important therapeutics into successful late stage trials and guided the successful re-focusing of its Custom Manufacturing Business.

Walter Korz, COO

Mr. Korz joined the Company in November 2010. His multi-disciplinary experience has spanned 25 years in the biotech sector with a number of emerging and established companies as well as 10 years in the public health care sector. Mr. Korz brings with him a broad drug development background with experience in business development, finance, clinical development, regulatory affairs, and project outsourcing. He previously served as Vice President, Drug Development and later stepping in as President and CEO of Chemokine Therapeutics Corp.

Mr. Korz held the position of Clinical Development Manager with Angiotech Pharmaceuticals, Inc. overseeing the systemic therapy programs including one of the largest multiple sclerosis clinical trials conducted in Canada. With AltaRex Corp. he was responsible for the development of therapeutic products while serving in Edmonton and Boston. His initial drug development, clinical, and regulatory experiences were gained with Biomira Research Inc. Mr. Korz was educated at the University of Alberta, Southern Alberta Institute of Technology and the University of Saskatchewan. He obtained his Masters of Business Administration from Athabasca University.

Andrew Buckland, CFO

Andrew Buckland has extensive experience in the development of financial operations within both large multinational corporations and early to mid-stage companies. He has a diverse background in international business as well as over fifteen years as the most senior financial officer of U.S. public and pre-IPO life sciences companies. Since 2012, Mr. Buckland has been the Chief Financial Officer of San Diego-based Polynoma LLC. In this role, he is responsible for all finance, accounting, treasury, human resources, information technology and risk management functions for a biotechnology company developing an immunotherapy for the treatment of melanoma, currently running one of the world’s largest global Phase III melanoma clinical trials. Like WEX, Polynoma is also a subsidiary of CK Life Sciences Int’l (Holdings), Inc.

Prior to his tenure at Polynoma, Mr. Buckland served as Chief Financial Officer of PURE Bioscience, Inc., a company he took from the OTC Bulletin Board to the NASDAQ Stock Market. Prior to PURE Bioscience, Mr. Buckland served as Vice President of Finance at Cardionet, Inc., as Chief Financial Officer of Advanced Tissue Sciences, Inc., a NASDAQ-listed public biotechnology company, and in significant international accounting and financial management positions at Bristol-Myers Squibb and United Parcel Service. He has completed several private placements and registered direct common stock offerings in the United States, and obtained SEC effectiveness on multiple registration statements.

Mr. Buckland earned an MBA from the University of California, Irvine and a BA (with Honors) from the University of the West of England.